$628.67
1.21% today
NYSE, Nov 21, 08:13 pm CET
ISIN
US58155Q1031
Symbol
MCK

McKesson Stock price

$621.14
+112.82 22.19% 1M
+57.14 10.13% 6M
+158.16 34.16% YTD
+168.17 37.13% 1Y
+399.07 179.70% 3Y
+470.44 312.17% 5Y
+416.14 203.00% 10Y
NYSE, Closing price Wed, Nov 20 2024
+5.49 0.89%
ISIN
US58155Q1031
Symbol
MCK
Sector

Key metrics

Market capitalization $78.85b
Enterprise Value $83.93b
P/E (TTM) P/E ratio 32.19
EV/FCF (TTM) EV/FCF 18.24
EV/Sales (TTM) EV/Sales 0.25
P/S ratio (TTM) P/S ratio 0.24
P/B ratio (TTM) P/B ratio negative
Dividend yield 0.39%
Last dividend (FY24) $2.40
Revenue growth (TTM) Revenue growth 13.43%
Revenue (TTM) Revenue $330.19b
EBIT (operating result TTM) EBIT $3.80b
Free Cash Flow (TTM) Free Cash Flow $4.60b
Cash position $2.51b
EPS (TTM) EPS $19.29
P/E forward 25.10
P/S forward 0.22
EV/Sales forward 0.23
Short interest 1.61%
Show more

Is McKesson a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

McKesson Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a McKesson forecast:

15x Buy
75%
5x Hold
25%

Analyst Opinions

20 Analysts have issued a McKesson forecast:

Buy
75%
Hold
25%

Financial data from McKesson

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
330,187 330,187
13% 13%
100%
- Direct Costs 317,590 317,590
14% 14%
96%
12,597 12,597
8% 8%
4%
- Selling and Administrative Expenses 8,145 8,145
24% 24%
2%
- Research and Development Expense - -
-
-
4,452 4,452
12% 12%
1%
- Depreciation and Amortization 651 651
25% 25%
0%
EBIT (Operating Income) EBIT 3,801 3,801
9% 9%
1%
Net Profit 2,536 2,536
27% 27%
1%

In millions USD.

Don't miss a Thing! We will send you all news about McKesson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

McKesson Stock News

Positive
Seeking Alpha
13 days ago
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven ...
Positive
The Motley Fool
14 days ago
McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net income.
Neutral
Seeking Alpha
15 days ago
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
More McKesson News

Company Profile

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other. The U.S. Pharmaceutical and Specialty Solutions segment distributes pharmaceutical and other healthcare-related products and also provides pharmaceutical solutions to pharmaceutical manufacturers in the United States. The European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers and serves patients and consumers in 13 European countries. The Medical-Surgical Solutions segment focuses on medical-surgical supplies and provides logistics and other services to healthcare providers in the United States. The Other segment comprises on McKesson Canada, McKesson Prescription Technology Solutions and in a joint venture. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Head office United States
CEO Brian Tyler
Employees 51,000
Founded 1833
Website www.mckesson.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today